BIOCON

Biocon Biologics is expanding its global footprint in biosimilars, particularly in oncology and diabetes care. Regulatory approvals in the US and Europe remain key catalysts. While near-term profitability may be volatile due to high R&D costs, long-term potential in biologics remains strong. Suitable for investors with higher risk appetite and long-term horizon.